View Older Stories View More Recent Stories

Feb 27, 2024 06:00AM BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Feb 26, 2024 06:00AM BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Feb 26, 2024 05:49AM BeiGene (BGNE) Reports Positive CHMP Opinion for Tislelizumab
Feb 26, 2024 05:00AM BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Jan 23, 2024 06:01AM BeiGene (BGNE) Appoints Olivier Brandicourt to its Board
Jan 23, 2024 06:00AM BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
Dec 22, 2023 06:00AM BeiGene (BGNE) Announces FDA Approval of Label Update for BRUKINSA in Chronic Lymphocytic Leukemia
Dec 22, 2023 06:00AM FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
Dec 21, 2023 06:01AM BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 29, 2023 04:01PM BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
Nov 28, 2023 06:00AM BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
Nov 21, 2023 06:01AM BeiGene (BGNE) and Ensem Announce Partnership to Advance Differentiated CDK2 Inhibitor
Nov 21, 2023 06:00AM BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
Nov 17, 2023 06:00AM BeiGene (BGNE) Announces EU Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Nov 17, 2023 06:00AM BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Nov 9, 2023 04:01PM BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
Nov 8, 2023 06:00AM BeiGene to Present at the Jefferies London Healthcare Conference
Oct 20, 2023 06:01AM BeiGene (BGNE) Reports BRUKINSA Receives Positive Recommendation from NICE in U.K.
Oct 20, 2023 06:00AM BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
Oct 17, 2023 04:02PM BeiGene (BGNE) Reports Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy
Oct 17, 2023 04:01PM BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junctio
Oct 17, 2023 04:01PM BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-S
Oct 16, 2023 06:00AM BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
Oct 13, 2023 11:51AM BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA in Relapsed or Refractory Follicular Lymphoma
Oct 13, 2023 11:51AM BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
Sep 19, 2023 06:15AM BeiGene (BGNE) Reports Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA
Sep 19, 2023 06:15AM BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
Aug 31, 2023 07:00AM BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 2, 2023 06:00AM BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
Jul 21, 2023 07:53AM BeiGene (BGNE) Receives Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
Jul 21, 2023 07:50AM BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
Jul 12, 2023 07:03AM BeiGene (BGNE) Announces FDA Acceptance of sNDA for Fifth BRUKINSA Indication
Jul 12, 2023 07:00AM BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
Jul 10, 2023 07:04AM BeiGene (BGNE), DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
Jul 10, 2023 07:00AM BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
Jul 7, 2023 07:00AM BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
Jun 17, 2023 04:21PM BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
Jun 15, 2023 08:38AM BeiGene (BGNE) to Defend Patent Infringement Allegations by Pharmacyclics
Jun 15, 2023 08:37AM BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
Jun 15, 2023 03:00AM BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
Jun 9, 2023 05:30AM BeiGene (BGNE) Highlights Promising Data from Blood Cancer Portfolio and Pipeline
Jun 9, 2023 03:01AM BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
May 30, 2023 07:04AM BeiGene' (BGNE) BRUKINSA Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 30, 2023 07:00AM BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 25, 2023 05:05PM BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 24, 2023 07:00AM BeiGene to Present at Upcoming Investor Conferences
May 17, 2023 07:00AM The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and
May 8, 2023 05:27AM BeiGene (BGNE) Receives New Approvals for BRUKINSA in China
May 6, 2023 08:00AM BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
May 4, 2023 07:00AM BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
View More Recent Stories View Older Stories